Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market
Q4 2024 Management View CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving profitability and implementing a share repurchase plan. Looking ahead, ...
Hosted on MSN36m
Texas Roadhouse (TXRH) Surpasses Q4 Earnings and Revenue Estimates
Texas Roadhouse (TXRH) came out with quarterly earnings of $1.73 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.08 per share a year ago. These ...